BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7632956)

  • 1. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
    Hertenstein B; Wagner B; Bunjes D; Duncker C; Raghavachar A; Arnold R; Heimpel H; Schrezenmeier H
    Blood; 1995 Aug; 86(4):1487-92. PubMed ID: 7632956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
    Taylor VC; Sims M; Brett S; Field MC
    Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
    Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
    Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion.
    Garland RJ; Groves SJ; Diamanti P; West SE; Winship KL; Virgo PF; Robinson SP; Oakhill A; Cornish JM; Pamphilon DH; Marks DI; Goulden NJ; Steward CG
    Bone Marrow Transplant; 2005 Aug; 36(3):237-44. PubMed ID: 15968291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
    Rowan W; Tite J; Topley P; Brett SJ
    Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.
    Rawstron AC; Rollinson SJ; Richards S; Short MA; English A; Morgan GJ; Hale G; Hillmen P
    Br J Haematol; 1999 Oct; 107(1):148-53. PubMed ID: 10520035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
    Rowan WC; Hale G; Tite JP; Brett SJ
    Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins.
    Schrezenmeier H; Hertenstein B; Wagner B; Raghavachar A; Heimpel H
    Exp Hematol; 1995 Jan; 23(1):81-7. PubMed ID: 7995374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
    Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
    Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PIG-anchoring defect in NK lymphocytes of PNH patients.
    Schubert J; Uciechowski P; Delany P; Tischler HJ; Kolanus W; Schmidt RE
    Blood; 1990 Sep; 76(6):1181-7. PubMed ID: 1698101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD52 expression in mantle cell lymphoma.
    Bass AJ; Gong J; Nelson R; Rizzieri DA
    Leuk Lymphoma; 2002 Feb; 43(2):339-42. PubMed ID: 11999566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria.
    Hernández-Campo PM; Almeida J; Sánchez ML; Malvezzi M; Orfao A
    Cytometry B Clin Cytom; 2006 Mar; 70(2):71-81. PubMed ID: 16493662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
    Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
    Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.